Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinostamustine in newly diagnosed unmethylated MGMT-promoter glioblastoma
NCT05432375Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tinostamustine in glioblastoma (GBM), sponsored by Mundipharma. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Jul 2022; status: completed.
02
Drugs
tinostamustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05432375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432375.